Chemotherapy-induced bladder cancer

Scandinavian Journal of Urology and Nephrology

Volumn 42, Issue SUPPL.218, 2008, Pages 89-92

  Nilsson, Sten ^a,b   Ullén, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bladder cancer; Chemotherapy; Cyclophosphamide; Secondary malignancy

Indexed keywords

ACROLEIN; CYCLOPHOSPHAMIDE; MELPHALAN; MESNA; THIOTEPA; ANTINEOPLASTIC AGENT;

BLADDER CANCER; CANCER CHEMOTHERAPY; CONFERENCE PAPER; DRUG BINDING; DRUG METABOLISM; HEMORRHAGIC CYSTITIS; HUMAN; PRIORITY JOURNAL; BLADDER TUMOR; CHEMICALLY INDUCED DISORDER; HEALTH; INCIDENCE; REVIEW; RISK FACTOR;

ANTINEOPLASTIC AGENTS; HUMANS; INCIDENCE; RISK FACTORS; URINARY BLADDER NEOPLASMS; WORLD HEALTH;

EID: 52949099909     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/03008880802291832     Document Type: Conference Paper

References (18)

1. Worth PH. Cyclophosphamide and the bladder. BMJ 1971;iii:182.
2. Pedersen-Bjergaard J, Ersboll J, Hansen VL, Hansen VL, Sørensen BL, Christoffersen K, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988;10:1028-32.
3. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995;87:524-30.
4. Pedersen-Bjergaard J, Jonsson V, Pedersen M, Hou-Jensen K. Leiomyosarcoma of the urinary bladder after cyclophosphamide. J Clin Oncol 1995;13:532-3.
5. Fernandes ET, Manivel JC, Reddy PK, Ercole CJ. Cyclophosphamide associated bladder cancer - a highly aggressive disease: analysis of 12 cases. J Urol 1996;156:1931-3.
6. Kaldor JM, Day NE, Kittelmann B, Pettersson F, Langmark F, Pedersen D, et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study. Int J Cancer 1995;63:1-6.
7. Tanguay C, Harvey I, Houde M, Srigley JR, Tetu B. Leiomyosarcoma of the urinary bladder following cyclophosphamide therapy: report of two cases. Mod Pathol 2003;16:512-4.
8. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002;100:82-5.
9. Stillwell TJ, Benson RC Jr. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer 1988;61:451-7.
10. Wong TM, Yeo W, Chan LW, Mok TS. Hemorrhagic pyelitis, ureteritis, and cystitis secondary to cyclophosphamide: case report and review of the literature. Gynecol Oncol 2000;76:223-5.
11. Kawamura J, Sakurai M, Tsukamoto K, Tochigi H. Leiomyosarcoma of the bladder eighteen years after cyclophosphamide therapy for retinoblastoma. Urol Int 1993;51:49-53.
12. Sigal SH, Tomaszewski JE, Brooks JJ, Wein A, LiVolsi VA. Carcinosarcoma of the bladder following long-term cyclophosphamide therapy. Arch Pathol Lab Med 1991;115:1049-51.
13. Povirk LF, Shuker DE. DNA damages and mutagenesis induced by nitrogen mustards. Mutat Res 1994;318:205-26.
14. Curren RD, Yang LL, Conklin PM, Grafstrom RC, Harris CC. Mutagenesis of xeroderma pigmentosum fibroblasts by acrolein. Mutat Res 1988;209:17-22.
15. Khan MA, Travis LB, Lynch CF, Soini Y, Hruszkewycz AM, Delgado RM, et al. P53 mutations in cyclophosphamide*associated bladder cancer. Cancer Epidemiol Biomarkers Prev 1998;7:397-403.
16. Spruck CH, Rideout WM, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, et al. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res 1993;53:1162-6.
17. Warren W, Biggs PJ, el-Baz M, Ghoneim MA, Stratton MR, Venitt S. Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. Carcinogenesis (Lond) 1995;16:1181-9.
18. Capizzi RL. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1996;23:2-17.